Search
Grace Therapeutics, Inc
GRCEAdd to Watchlist
2.170USD
+0.010+0.46%
Market hours （ET）Quotes delayed by 15 min
35.31MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of Grace Therapeutics, Inc is 8.00, ranking 170 out of 387 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 12.00 and a low of 11.00.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
6.000
Target Price
+177.78%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Grace Therapeutics, Inc
GRCE
2
argenx SE
ARGX
28
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Grace Therapeutics, Inc's price target?
Analysts forecast that Grace Therapeutics, Inc's price target is USD 12.00, with the highest forecast at USD 12.00 and the lowest forecast at USD 11.00.
How have Grace Therapeutics, IncGRCE's recent earnings per share performed?
The market expectation was USD -0.91, while Grace Therapeutics, IncGRCE's earnings per share (EPS) for the previous quarter was USD -0.07. EPS for the next quarter is expected at USD -0.13.
What is the analyst rating for Grace Therapeutics, Inc?
Based on the ratings of Grace Therapeutics, Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.